Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global immunohematology market was valued at US$ 1.01 billion in 2021 and is expected to register a revenue CAGR of 3.90% to reach US$ 1.41 billion by 2030.

Invasive Aspergillosis Therapeutics Market Fundamentals 

Aspergillosis is a disease caused by the fungus Aspergillus. Invasive aspergillosis can occur in individuals with a weakened immune system. It is a major cause of morbidity and mortality in immunocompromised patients, such as those undergoing chemotherapy or organ transplantation.

Depending on the host immune system condition, Aspergillus can cause various diseases, such as allergic reactions, invasive lung infections, and infections of other organs. Lungs and paranasal sinuses are the main infection sites. Early diagnosis and treatment of invasive aspergillosis is crucial as the infection can rapidly become life-threatening. Direct invasion from the paranasal sinuses and hematogenous dissemination are the two causes of cerebral involvement.

[8482924]

Invasive Aspergillosis Therapeutics Market Dynamics

Availability of novel treatments and diagnostic tests for invasive aspergillosis is driving the revenue growth of this market. Growing awareness about the disease among healthcare professionals and patients, increasing healthcare expenditures, and government initiatives for early diagnosis and treatment are contributing to the revenue growth of the global invasive aspergillosistherapeutics market.

As immunosuppressive therapies are used more frequently, more patients are at risk for developing this condition. Mostly, people who undergo organ transplantation require immunosuppressive therapies. High recommendation of voriconazole by healthcare professionals is helping in boosting revenue growth in the market.

Rising cases of COPD and asthma are expected to indirectly influence the market growth revenue during the forecast period. Increasing number of pipeline drugs is projected to fuel the demand for invasive aspergillosis therapeutics.

However, different Aspergillus species have different levels of intrinsic resistance to azoles. They are all inherently resistant to fluconazole and ketoconazole due to a naturally occurring amino acid substitution in the enzyme 14-sterol demethylase A, which CYP51A encodes. This factor, in turn, is likely to limit the revenue growth of the global market in the next few years. 

Invasive Aspergillosis Therapeutics Market Ecosystem

The global invasive aspergillosis therapeutics market is analyzed from three perspectives: drug class, route of administration, and region.

Invasive Aspergillosis Therapeutics Market by Drug Class

[1245683]

Based on the drug class, the market is segmented into azoles and antibiotics. 

The azoles segment accounts for the majority of the revenue share of the market. Azoles work by inhibiting the fungus growth, which helps reduce the severity of symptoms and prevent further damage. Azoles may sometimes be combined with other treatments, such as surgery or immunotherapy, to provide more effective relief. Azoles effectively treat various forms of invasive aspergilloses, such as pulmonary and disseminated forms. Additionally, studies have shown that azoles can help reduce mortality rates associated with this condition. Significant advances in research into the azole class of antifungal agents expanded treatment options for many opportunistic and endemic fungal infections. Among azoles, voriconazole is the primary treatment of invasive aspergillosis. Voriconazole is effective in vitro against various yeasts, molds, and Aspergillus species. According to a non-comparative study covered by the New England Journal of Medicine, patients with invasive aspergillosis had a response rate of 48%. A significant number of azole drugs in the pipeline contribute to the segment growth. For instance, TFF VORI inhaled voriconazole by TFF Pharmaceuticals is currently in phase 2 to treat invasive aspergillosis.

Invasive Aspergillosis Therapeutics Market by Route of Administration

Based on the route of administration, the market is segmented into oral and parenteral drugs. 

The oral segment dominates the market owing to the availability of major drugs in the oral route of aspergillosis. For instance, voriconazole and posaconazole are antifungal medications used to treat invasive aspergillosis. Both medications effectively treat this condition, with voriconazole being the preferred drug due to its higher success rate and fewer side effects. However, both drugs can cause serious side effects and should only be used with caution and under the supervision of a doctor. Side effects, such as nausea, vomiting, headache, rash, and liver damage, can occur with either medication. Posaconazole (Noxafil) is recommended in patients at high risk for invasive Aspergillus and Candida infections due to severe immunosuppression. It comes in oral solution (200 mg/5 mL), delayed-release tablet (100 mg), and injectable forms. Moreover, oral voriconazole is advised for patients with invasive aspergillosis. L-AmB therapy can work as a key alternative treatment for patients resistant to or intolerant of voriconazole. 

Invasive Aspergillosis Therapeutics Market by Region

Based on the region, the global invasive aspergillosis therapeutics market therapy market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). 

North America dominates the global invasive aspergillosis therapeutics market due to increasing number of patients undergoing organ transplantation. Furthermore, rising number of R&D activities is influencing the market revenue growth in this region. Moreover, presence of a significant number of market players, such as SCYNEXIS, Inc., TFF Pharmaceuticals, and Mylan Pharmaceuticals, Inc., in the region is supporting the revenue growth of the market.

The market in Asia Pacific is expected to register a high revenue CAGR during the forecast period. Invasive aspergillosis is a major public health concern in the Asia Pacific, particularly in countries with high levels of air pollution and poor hygiene. Rising patient population and increasing R&D activities are influencing the Asia Pacific market revenue growth. 

Invasive Aspergillosis Therapeutics Market Competitive Landscape 

The prominent players operating in the invasive aspergillosis therapeutics market are:

• F2G Ltd.
• SCYNEXIS, Inc.
• Pulmocide Ltd
• TFF Pharmaceutical, Inc.
• Biosergen AB
• Basilea Pharmaceutical International Ltd. 
• Mylan Pharmaceuticals, Inc.
• Novartis AG
• GlaxoSmithKline plc
• Johnson & Johnson Services Inc. 

Frequently Asked Questions About This Report